Comparing outcomes in patients with persistent asthma: a registry of two therapeutic alternatives

Abstract
Objective: Clinical trials have demonstrated improved efficacy of fluticasone propionate/ salmeterol (100/50 mcg) in a single device (FSC) compared with montelukast (10 mg) (MON). This study was designed to assess asthma control, asthma-related quality of life, asthma-related emergency department (ED) visit/hospitalization, treatment-related satisfaction, and productivity losses in patients newly started on FSC or MON.Research design and methods: Patients who were newly prescribed FSC or MON during a regularly scheduled office visit were enrolled in a prospective observational study by nearly 500 physicians from eight managed care plans. Patient survey data were collected at baseline and at months 1, 3, 6, and 12, to measure study outcomes. ED visits/inpatient stays were reported from commercial claims data. Multivariate analyses assessed 12‐month outcomes, controlling for several baseline patient characteristics.Results: A total of 1414 patients ≥ 15 years old were enrolled in the registry (FSC, ...

This publication has 31 references indexed in Scilit: